$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.
Cetya Therapeutics, Inc. announces the award of a $170,000 Advanced Industries grant from the State of Colorado to support the development of its proprietary receptor ligand-targeted histone deacetylase (HDAC) inhibitors. Targeting has been an effective method for dealing with drug-related toxicities, and with this novel technology, Cetya seeks to address one of the primary impediments to the widespread use of HDAC inhibitors in the treatment of cancer.
HDAC inhibitors are approved in the United States by the FDA for use in treating two types of blood cancers, cutaneous T-cell lymphoma and multiple myeloma. The performance of HDAC inhibitors in the treatment of solid tumors, however, has not met expectations, and none are approved for a solid tumor indication. One of the challenges in the treatment of solid tumors is penetrance; it is difficult to get the drug into the tumor. By attaching a receptor ligand to the chemical structure of Cetya’s HDAC inhibitors, we anticipate improved accumulation of the drug in the tumor tissue, and therefore therapeutic benefit, driven by the active uptake of the drug through the cell surface receptor.
“I am excited by the potential for Cetya’s targeted HDAC inhibitors. This novel approach could overcome the limitations that have impeded the widespread use of HDAC inhibitors for treatment of solid tumors,”stated Dr. Samir Witta, a practicing medical oncologist based in Golden, Colorado and affiliated with the University of Colorado Denver Cancer Center. Cetya’s largazole analogs represent an opportunity to develop HDAC inhibitors that may mitigate dose-limiting toxicities and serious adverse events that have plagued HDAC inhibitor drug development. Cetya’s analogs have the potential to address solid tumor indications, and possibly therapeutic areas outside of oncology, such as sickle cell disease. Cliff Hendrick, CEO of Cetya, stated, “The Advanced Industries grant from the State of Colorado is a great opportunity for Cetya to accelerate the development of its proprietary targeted HDAC inhibitors, and gain supporting evidence that this approach will lead to successful employment of HDAC inhibitors in the treatment of solid tumors such as lung and ovarian cancer.”
Cetya has the exclusive worldwide rights to the histone deacetylase (HDAC) inhibitor patent estate developed in the laboratory of Dr. Robert Williams, University Distinguished Professor of Chemistry at Colorado State University. Three US patents have issued to date, and two more applications are pending, both of which have filed internationally. One of those applications protects the technology supported by the current award from Colorado.
You can read more about this from the original article here.